SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Fancy who wrote (4664)7/1/1998 12:08:00 AM
From: Izzy  Read Replies (2) of 6136
 
Another treatment opinion: "Leading experts at the XII World AIDS Conference in Geneva presented data that support the use of a treatment regimen that includes two protease inhibitors as first-line therapy for HIV and AIDS. The growing importance of dual protease therapy has emerged as a major treatment trend." Perhaps someone out there can post the entire article (I can't). I completely agree with Rick's earlier statement that Sustiva, and other proposed drugs, does not impact the use of Viracept, at least at this time or in the near future (1-2 yrs out). However, I do suspect that ABT's Norvir will most likely be the next major PI on the market. Fortunately for me, I had already sold VRTX, which was down 5 1/8 today to 22 1/2, an incredibly low price. I'm losing enough on AGPH but I fully expect to make a recovery into the "black." Steve, sorry, I'm not into options, but I appreciate the info. Better luck to all of us tomorrow (except the shorts).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News